COLAND PHARMACEUTICAL

Kanglian Holdings has developed in the Chinese medical market as a medical platform industry focused on the development and marketing of professional pharmaceutical products and looking at the global market. Since its establishment 10 years ago, the company has developed high-efficiency and safe quality medical products with a unique business model, and is committed to creating the greatest value of the medical industry. In 2005, Kanglian Holdings established a stable marketing scale and market base for the treatment of hepatitis B. In recent years, it has continued to introduce new products. The current product projects cover hepatitis, respiratory system, cardiovascular, medical equipment and testing reagents.